Because it sure doesnt seem like it, does it
Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia
doi: 10.1089/met.2018.0075 169 UkkolaOHPuurunenV-PPiiraO-PNivaJTLepojrviESTulppoMPet al
The company began to study GLP-1s for both diabetes and weight loss
The incidence of injection site reactions with By dur eon is about 20%, which is much higher than any other GLP analogYour skin better be dur able